Year in review 2023 - Back to the future.
J Cyst Fibros
; 23(2): 203-207, 2024 Mar.
Article
en En
| MEDLINE
| ID: mdl-38431442
ABSTRACT
This review synthesizes articles published in 2023, focusing on the impact of elexacaftor-tezacaftor-ivacaftor (ETI) in cystic fibrosis (CF) care. Real-world data highlights sustained benefits of ETI across age groups, while challenges like neuropsychological side effects persist. Beyond CFTR modulators, research explores telemedicine and novel therapies. Prioritizing equitable access and addressing unmet needs remain crucial for comprehensive CF management.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fibrosis Quística
/
Aminofenoles
Límite:
Humans
Idioma:
En
Revista:
J Cyst Fibros
Año:
2024
Tipo del documento:
Article